Monitor upcoming earnings or clinical updates — the divergence between executive selling and external investor buying may reflect profit-taking post-runup rather than fundamental concerns. Watch for follow-up trades from other insiders or Lindstrom adding to his position.
Price Chart
Executive Summary
A cluster of insider transactions at Ocular Therapeutix (OCUL) over the past week shows mixed activity: one significant open-market purchase by external investor Dr. Richard Lindstrom for $461K, alongside coordinated open-market sales by five insiders including four C-suite executives totaling $256K. The selling is concentrated among senior leadership, while the sole buyer is not an executive officer, suggesting divergent sentiment.
Key Financial Metrics
Key Facts
- Dr. Richard L. Lindstrom, MD, purchased 60,229 shares at $7.66 for $461,354.14 on February 20, 2026, in an open-market transaction.
- Four C-suite executives — Pravin Dugel, Peter Kaiser, Jeffrey Heier, Sanjay Nayak, and Nadia Waheed — sold shares between February 20 and February 23, 2026.
- Total insider selling volume: 31,192 shares, valued at $256,374.36 across five transactions.
- All sales were open-market transactions (Form 4 code 'S'), not forced or tax-related dispositions.
- Selling executives represent key roles in development, science, strategy, and medical affairs.
Financial Impact
Net insider selling of $256K offset by $461K external purchase; no direct financial impact to company balance sheet but potential signal on internal sentiment.
Risk Factors
- Coordinated C-suite selling could signal lack of confidence in near-term prospects, especially if not part of a pre-arranged plan.
- The purchase by Lindstrom, while notable, comes from a non-executive and may not reflect internal views on valuation or pipeline risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-OCUL-1772103655330 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access